Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, New England Journal of Medicine, 364, 1207, 10.1056/NEJMoa1009482 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, New England Journal of Medicine, 364, 2405, 10.1056/NEJMoa1012912 Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, New England Journal of Medicine, 364, 1195, 10.1056/NEJMoa1010494 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, New England Journal of Medicine, 364, 2417, 10.1056/NEJMoa1013086 Pawlotsky, 2011, Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus, Hepatology, 53, 1742, 10.1002/hep.24262 Soriano, 2008, Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?, Journal of Antimicrobial Chemotherapy, 62, 1, 10.1093/jac/dkn175 Ribeiro, 2012, Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate, PLoS Pathogens, 8, e1002881, 10.1371/journal.ppat.1002881 Martell, 1992, Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution, Journal of Virology, 66, 3225, 10.1128/jvi.66.5.3225-3229.1992 Rong, 2010, Rapid emergence of protease inhibitor resistance in hepatitis C virus, Science Translational Medicine, 2, 30ra32, 10.1126/scitranslmed.3000544 Guedj, 2011, Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration, Hepatology, 53, 1801, 10.1002/hep.24272 Neumann, 1998, Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science, 282, 103, 10.1126/science.282.5386.103 Rosen, 2002, Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy, Journal of Hepatology, 37, 124, 10.1016/S0168-8278(02)00114-9 Dixit, 2004, Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature, 432, 922, 10.1038/nature03153 Chatterjee, 2012, Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?, Antiviral Therapy, 17, 1171, 10.3851/IMP2428 European Medicines Agency (EMA), 2011 Guedj, 2010, Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics, Journal of Theoretical Biology, 267, 330, 10.1016/j.jtbi.2010.08.036 Cento, 2012, HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors, PLoS ONE, 7, e39652, 10.1371/journal.pone.0039652 Zagordi, 2011, ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data, BMC Bioinformatics, 12, 119, 10.1186/1471-2105-12-119 Tamura, 2011, MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods, Molecular Biology and Evolution, 28, 2731, 10.1093/molbev/msr121 Nasu, 2011, Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing, PLoS ONE, 6, e24907, 10.1371/journal.pone.0024907 Cento, 2013, NS3-resistance in advanced HCV patients treated with BOC/TRV-based therapy: impact on virological failure of baseline and early time points. The Liver Meeting 2013, AASLD Abstracts, Hepatology, 58, 1960 Taylor, 2014, Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays – implications for response-guided therapy in genotype 1 infections, Antiviral Therapy, 19, 449, 10.3851/IMP2723